Featured Chrome Extensions:

Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

plaintiffinjunctionmotion
plaintiffdefendantinjunctionmotionwill

Related Cases

Doe v. Ladapo, 676 F.Supp.3d 1205, 29 Fla. L. Weekly Fed. D 177
View Case »
Hecox v. Little, 479 F.Supp.3d 930, 107 Fed.R.Serv.3d 758, 385 Ed. Law Rep. 657
View Case »
Doe 1 v. Thornbury, 679 F.Supp.3d 576
View Case »
Ondo v. City of Cleveland, 795 F.3d 597
View Case »
Alliance for Hippocratic Medicine v. U.S. Food & Drug Administration, 78 F.4th 210, Med & Med GD (CCH) P 307,800
View Case »
Justia Law Link
LexisNexis Link
Westlaw Link
CourtListener Link
Oyez Link

Washington v. United States Food and Drug Administration, 668 F.Supp.3d 1125, Med & Med GD (CCH) P 307,689

Facts

The case arose from the FDA's implementation of a new REMS for mifepristone, which included restrictions on its dispensing and use. The states argued that these restrictions were unnecessary given the drug's safety record and sought to affirm the FDA's original conclusion that mifepristone is safe and effective. The court noted that the FDA had previously approved mifepristone under less restrictive conditions and that the states had standing to challenge the new REMS.

Plaintiffs, on behalf of themselves and as parens patriae in protecting the health and well-being of its residents, moves for a preliminary injunction 'affirming FDA's original conclusion that mifepristone is safe and effective, preserving the status quo by enjoining any actions by Defendants to remove this critical drug from the market, and enjoining the unnecessary and burdensome January 2023 restrictions.'

Issue

Did the states establish standing to challenge the FDA's new REMS for mifepristone, and were the restrictions imposed by the FDA arbitrary and capricious under the Administrative Procedure Act?

Did the states establish standing to challenge the FDA's new REMS for mifepristone, and were the restrictions imposed by the FDA arbitrary and capricious under the Administrative Procedure Act?

Rule

Under the Administrative Procedure Act, a plaintiff must demonstrate standing, show likelihood of success on the merits, and establish irreparable harm to obtain a preliminary injunction.

To obtain this relief, a plaintiff must demonstrate: (1) a likelihood of success on the merits; (2) a likelihood of irreparable injury in the absence of preliminary relief; (3) that a balancing of the hardships weighs in plaintiff's favor; and (4) that a preliminary injunction will advance the public interest.

Analysis

The court found that the states had established standing based on their economic interests and the likelihood of irreparable harm due to the new REMS. It noted that the states had serious questions regarding the merits of their claims, particularly whether the FDA's restrictions were necessary given the drug's safety profile. The court emphasized that the FDA had not adequately considered whether mifepristone still required a REMS.

The Court finds there are serious issues going to the merits of Plaintiffs’ APA claims.

Conclusion

The court granted the states' motion for a preliminary injunction in part, allowing them to maintain the status quo regarding mifepristone's availability while denying a nationwide injunction. The court found that the states had shown a likelihood of success on the merits and irreparable harm.

Motion for preliminary injunction granted in part; motions for leave to file amicus briefs denied.

Who won?

The states prevailed in part, as the court allowed them to maintain the status quo regarding mifepristone's availability, finding that they had established standing and serious questions regarding the merits of their claims.

The Court has reviewed the record and files herein, and is fully informed.

You must be